查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1992527

血液管路套装市场：按类型、材料、最终用户和应用划分－2026-2032年全球市场预测

Blood Tubing Set Market by Type, Material, End-User, Usage - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年血液输液管路套装市值为10.4亿美元，预计2026年将成长至11.2亿美元，复合年增长率为7.31%，到2032年将达到17.1亿美元。

主要市场统计数据
基准年 2025 10.4亿美元
预计年份：2026年 11.2亿美元
预测年份 2032 17.1亿美元
复合年增长率 (%) 7.31%

这是一部重点突出、注重实践的介绍性文章，说明了影响现代血液管路套装策略的临床、材料、监管和商业性趋势。

本执行摘要概述了血液输液管路组件的现状，这是一个复杂且快速发展的领域，并阐述了影响采购和临床实践的技术、监管和商业性因素。血液输液管路组件融合了医疗设备设计、生物相容性材料科学以及严格的灭菌和安全通讯协定，所有这些因素共同决定了其临床适用性和采购偏好。该行业服务于多种临床路径，包括血浆置换、血液透析和输血，每种路径对管路组件的配置、耐用性和与辅助设备的兼容性都有独特的要求。

本报告探讨了正在重新定义整个产业的产品设计、安全和供应链整合的技术、监管和营运转折点。

受技术、监管和营运等多方面因素的影响，血液管材市场格局正经历变革性变化。材料和挤出製程的创新使得管材能够更纤细、更柔韧、更易萃取，从而降低不利事件风险，并方便临床医生操作。同时，灭菌方法和包装的创新在降低污染风险的同时，也满足了分散式医疗环境中长期储存的需求。

对近期关税调整如何影响关键消耗品的采购选择、製造地策略和供应商多元化进行全面分析。

近期关税措施为依赖进口医疗耗材的机构的采购、成本管理和供应链策略带来了新的变数。关税调整可能导致不同采购区域之间成本出现显着差异，并促使企业重新评估长期供应商关係。采购团队可以采取措施来减轻关税结构变化的影响，例如供应商多元化、增加本地库存缓衝或加快替代供应商的认证流程。

从洞察市场、细分的主导出发，解释了类型、材料、最终用户环境、销售管道以及一次性产品和可重复使用产品之间的观点动态如何对采购和设计选择产生重大影响。

细分市场分析揭示了每种类型、材料、终端用户环境、销售管道和使用模式的不同驱动因素和风险特征。用于血液分离术的产品需要特殊的流量控制和高化学相容性。血液透析套装则需要持久耐用和耐受频繁操作，而输血套装则优先考虑易用性和严格的无菌性，以便快速床边输注。材料选择进一步细分了产品线。聚氯乙烯(PVC) 因其柔软性和熟悉的製造特性而仍然很常见，但热可塑性橡胶(TPE) 为减少增塑剂用量和提高生物相容性提供了机会，从而影响临床接受度和监管审批进程。

这项详细的区域分析考察了美洲、欧洲、中东和非洲以及亚太地区的监管复杂性、采购结构和医疗保健服务体系的演变有何不同。

区域趋势导致各主要地区在监管预期、采购行为和供应韧性方面有显着差异。在美洲，严格的监管合规和完善的机构采购框架备受重视，推动了对检验的产品和全面的供应商服务模式的需求。分销网络普遍成熟，主要面向医院系统和大规模透析服务提供者。在欧洲、中东和非洲，报销方案的多样性和监管协调工作为寻求市场准入的製造商带来了机会和挑战，区域核准流程和各国特定的采购惯例影响着其市场部署策略。在亚太地区，医疗基础设施的快速扩张和慢性病负担的加重推动了对透析和输血相关耗材的需求，但供应链的波动性和品质标准的差异性要求企业采取个人化的市场准入和宣传策略。

竞争定位的策略性回顾：展示成熟製造商、利基创新者和契约製造製造商如何塑造其能力、供应弹性和临床部署。

血液输液管路市场的竞争动态呈现出多元化的态势，既有成熟的医疗设备製造商，也有专业的零件供应商，还有专注于材料科学和连接性改进的小规模创新企业。大型製造商在监管申报、全球分销基础设施和服务水准保障方面拥有规模经济优势，能够透过整合的供应合约和物流解决方案，为大规模医院系统和透析网路提供服务。同时，专业供应商往往凭藉快速的产品改进、与特定领域的临床伙伴关係建立合作关係以及差异化的材料技术（例如解决萃取、灭菌兼容性或人体工学操作方面的难题）来获得市场支持。

为供应商和买家提供简洁明了且切实可行的建议，以增强供应韧性、加速产品创新，并使采购与临床安全目标保持一致。

行业领导者应优先考虑平衡短期业务永续营运和中期创新，以保持竞争力并支持临床疗效。首先，透过认证跨区域的多家製造商，并在合约中加入关税、前置作业时间和品质补救措施等条款，来加强供应商组合。透过协作预测和风险分担机制，加强与供应商的关係，以降低意外短缺的可能性，并实现从中断中快速恢復。其次，投资于材料和设计方面的创新，以减少对有争议的供应链投入的依赖，并提高在医院和居家照护环境中的易用性。此类投资将有助于降低整体医疗保健成本，并提高临床医生的满意度。

对用于产生可操作的临床和采购见解的多方法研究过程、资料检验技术和专家参与方法进行透明的解释。

本研究采用结构化、多面向的方法，以确保研究结果的可靠性、检验以及对决策者的意义。主要资料收集包括对临床负责人、采购专家和生产品质专家的访谈，以了解实际营运、医疗设备相容性挑战以及供应链优先事项。次要研究则利用监管出版刊物、标准文件和同行评审文献，以当前安全性和性能预期为分析基础。必要时，也会交叉引用产品规格和技术白皮书，检验有关材料、灭菌相容性和仪器介面的说法。

一份权威总结，重点阐述了在不断变化的环境中，为确保临床连续性、产品安全性和采购韧性所需的策略重点和协作努力。

总之，血液输液管路领域正处于一个转折点，材料创新、监管趋严性以及供应链的灵活性将决定哪些公司能够成功满足不断变化的临床需求。医疗服务提供者和供应商必须权衡各种相互衝突的挑战：最大限度地减少污染和临床风险，持续控制耗材成本，并在贸易和物流不确定性中维持供应的连续性。那些能够整合卓越产品设计、灵活采购和数位化可追溯性的企业，将更有能力支援不断扩展的医疗模式，例如家庭护理和高通量透析环境。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：采血管市场：依类型划分

  • 血浆分离套装
  • 血液透析套装
  • 输血包

第九章：采血管市场：依材料分类

  • 聚氯乙烯
  • 热可塑性橡胶

第十章：采血管市场：依最终用户划分

  • 诊所
  • 透析中心
  • 居家医疗
  • 医院

第十一章：按应用分類的血液试管市场

  • 可重复使用的
  • 一次性的

第十二章：采血管市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：血液试管套装市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：血管套装市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国血液试管市场

第十六章：中国血管套装市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Angiplast Private Limited
  • Asahi Kasei Corporation
  • B. Braun Melsungen AG
  • Baxter International Inc
  • Becton Dickinson and Company
  • Cardinal Health
  • Danaher Corporation
  • Fresenius Kabi AG
  • GE HealthCare Technologies Inc
  • Gerresheimer AG
  • Haemonetics Corporation
  • Hemant Surgical Industries Ltd
  • ICU Medical Inc
  • JMS Co., Ltd.
  • Medtronic Plc
  • Merit Medical Systems Inc
  • Nipro Corporation
  • NxStage Medical
  • Shandong Weigao Group Medical Polymer
  • Smith & Nephew PLC
  • Smiths Medical
  • Terumo Corporation
  • Thermo Fisher Scientific
  • Vyaire Medical
Product Code: MRR-3204321AFA43

The Blood Tubing Set Market was valued at USD 1.04 billion in 2025 and is projected to grow to USD 1.12 billion in 2026, with a CAGR of 7.31%, reaching USD 1.71 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.04 billion
Estimated Year [2026] USD 1.12 billion
Forecast Year [2032] USD 1.71 billion
CAGR (%) 7.31%

A focused and practical introduction that contextualizes clinical, material, regulatory, and commercial dynamics shaping contemporary blood tubing set strategies

This executive summary introduces the complex and rapidly evolving blood tubing set landscape, framing the technical, regulatory, and commercial forces that are shaping procurement and clinical practice. Blood tubing sets operate at the intersection of medical device design, biocompatible materials science, and strict sterilization and safety protocols, which together determine clinical suitability and procurement preferences. The industry serves diverse clinical pathways including apheresis, hemodialysis, and blood transfusion, and each pathway imposes distinct requirements on set configuration, durability, and compatibility with ancillary equipment.

Throughout this summary, the aim is to synthesize recent developments into actionable context for decision-makers. Emphasis is placed on how material selection, single-use versus reusable paradigms, and channel dynamics influence adoption and supply resilience. Additionally, regulatory trajectories and reimbursement pressures are evaluated for their role in procurement decision-making and product innovation. By focusing on operational drivers and risk factors, readers will gain a clear sense of where investment, design refinement, and supply-chain attention should be prioritized to support patient safety and operational efficiency across clinical settings.

An exploration of the technological, regulatory, and operational inflection points that are redefining product design, safety, and supply integration across the sector

The landscape for blood tubing sets is undergoing transformative shifts driven by converging technological, regulatory, and operational pressures. Innovations in materials and extrusion processes are enabling slimmer profiles, enhanced kink resistance, and lower extractables, which in turn reduce adverse event risks and improve handling for clinicians. Meanwhile, sterility assurance methods and packaging innovations are reducing contamination risk while accommodating extended shelf-life needs in distributed care environments.

Operationally, the industry is moving toward modularity and compatibility as healthcare providers aim to standardize interfaces across devices to reduce training burden and inventory complexity. Concurrently, advances in remote monitoring and connected device ecosystems are encouraging integration of tubing sets with sensors that flag flow integrity or detect occlusions, thereby enabling earlier clinical intervention. Regulatory emphasis on post-market surveillance and traceability is accelerating adoption of unique device identifiers and serial tracking for critical consumables, prompting manufacturers to invest in supply-chain transparency and digital labeling. Taken together, these shifts are realigning priorities toward safety, interoperability, and data-enabled lifecycle management.

A comprehensive review of how recent tariff adjustments are reshaping procurement choices, manufacturing location strategies, and supplier diversification for critical consumables

Recent tariff actions have introduced new variables into procurement, cost management, and supply-chain strategy for organizations that rely on imported medical consumables. Tariff adjustments can create abrupt cost differentials between sourcing regions and prompt a re-evaluation of long-standing supplier relationships. Procurement teams may respond by diversifying supplier bases, increasing local inventory buffers, or accelerating qualification of alternative suppliers to mitigate exposure to changing duty structures.

Beyond immediate cost impacts, tariffs influence longer-term strategic decisions such as onshoring or nearshoring manufacturing, investing in automation to offset labor cost increases, and renegotiating contracts to include duty-inclusive pricing clauses. Clinical operations may encounter transitional friction as validated supply streams are adapted to new sources, requiring additional device compatibility testing and regulatory filings in some jurisdictions. Importantly, tariff-driven shifts also affect innovation pacing: manufacturers weighing capital investments may reassess timelines for facility expansion or tooling relocations in the context of evolving trade policy. As a result, both buyers and suppliers must maintain scenario-ready sourcing strategies and tighter collaboration to preserve continuity of care and control total cost of ownership.

Insightful segmentation-driven perspective explaining how type, material, end-user setting, channel, and single-use versus reusable dynamics materially affect procurement and design choices

Segment-level analysis reveals differentiated drivers and risk profiles across types, materials, end-user settings, sales channels, and usage models. Products designed for apheresis sets demand specialized flow control features and high chemical compatibility, whereas hemodialysis sets require sustained durability and resistance to frequent handling, and transfusion sets prioritize ease of use and strict sterility for rapid bedside administration. Material choices further stratify offerings: polyvinyl chloride remains common due to its flexibility and manufacturing familiarity, while thermoplastic elastomer presents opportunities for reduced plasticizer use and enhanced biocompatibility, influencing both clinical acceptance and regulatory review trajectories.

End-user environments impose distinct procurement and design imperatives. Clinics and dialysis centers often prioritize cost-efficiency and throughput, homecare settings emphasize simplified interfaces and caregiver-friendly designs, and hospitals require compatibility with a broad array of ancillary devices and adherence to institutional procurement standards. Sales channels shape access and service levels, with distributors and hospital pharmacies supporting bulk procurement and integrated logistics, online channels facilitating rapid replenishment for decentralized settings, and retail pharmacies offering patient-directed availability. Usage paradigms also bear on lifecycle decisions: reusable sets necessitate validated reprocessing protocols and capital investments in cleaning infrastructure, while single-use products simplify workflow and lower cross-contamination risk at the expense of recurring consumable spend. Synthesizing these segmentation dimensions highlights where manufacturers and purchasers should align product features, pricing models, and service offerings to match clinical workflows and regulatory expectations.

A nuanced regional analysis detailing how regulatory complexity, procurement structures, and healthcare delivery evolution differ across the Americas, Europe Middle East & Africa, and Asia-Pacific landscapes

Regional dynamics produce clear variations in regulatory expectations, purchasing behavior, and supply resiliency across major geographic groupings. In the Americas, a strong emphasis on rigorous regulatory compliance and established institutional procurement frameworks drives demand for validated products and comprehensive supplier service models, while distribution networks are typically mature and oriented toward hospital systems and large dialysis providers. In Europe, Middle East & Africa, heterogeneity in reimbursement systems and regulatory harmonization efforts creates both opportunities and complexity for manufacturers seeking market entry, with localized approval pathways and country-specific procurement practices shaping rollout strategies. In the Asia-Pacific region, rapid expansion of healthcare infrastructure and rising chronic disease burdens are increasing demand for dialysis and transfusion-related consumables, but supply-chain volatility and varying quality standards require tailored market access and education efforts.

Across all regions, geopolitical shifts and transport disruptions underscore the importance of regional manufacturing capacity and responsive logistics. Local clinical preferences and budget cycles further influence product design choices and inventory strategies, necessitating flexible pricing models and service commitments from suppliers. As healthcare delivery extends beyond hospitals into homecare and ambulatory settings globally, regional players must anticipate changing distribution patterns and adapt their commercialization tactics to maintain continuity of care while meeting diverse regulatory expectations.

A strategic review of competitive positioning showing how established manufacturers, niche innovators, and contract producers are shaping capability, supply resilience, and clinical adoption

Competitive dynamics in the blood tubing set domain reflect a blend of established medical device firms, specialized component manufacturers, and smaller innovators focused on material science or connectivity enhancements. Larger manufacturers bring scale advantages in regulatory submissions, global distribution infrastructures, and service-level guarantees, enabling them to serve major hospital systems and large dialysis networks with consolidated supply agreements and integrated logistics solutions. Conversely, specialized suppliers often gain traction through rapid product iteration, niche clinical partnerships, and differentiated material technology that addresses extractables, sterilization compatibility, or handling ergonomics.

Partnerships between OEMs and device integrators are increasingly common as manufacturers aim to ensure compatibility across therapeutic platforms and to embed traceability features into consumables. Contract manufacturing organizations and regional producers play a pivotal role in mitigating supply risk and enabling localized certifications, which can accelerate access to markets with stringent import regimes. Investors and corporate development teams are showing interest in firms that blend advanced materials expertise with scalable manufacturing processes, as these combinations can speed regulatory acceptance and lower lifecycle costs for providers. Overall, success favors organizations that combine rigorous quality systems, responsive customer support, and iterative product development aligned to evolving clinical workflows.

A concise set of pragmatic recommendations for suppliers and buyers to enhance supply resilience, accelerate product innovation, and align procurement with clinical safety objectives

Industry leaders should prioritize actions that balance immediate operational resilience with medium-term innovation to remain competitive and to support clinical outcomes. First, fortify supplier portfolios by qualifying multiple manufacturers across regions and by incorporating contractual terms that address tariffs, lead times, and quality recourse. Strengthening supplier relationships through collaborative forecasting and shared risk mechanisms will reduce the likelihood of unexpected shortages and enable faster recovery from disruptions. Second, invest in material and design innovation that reduces dependence on contentious supply-chain inputs and that enhances ease of use for bedside and homecare settings; such investments can yield lower total cost of care and improved clinician satisfaction.

Third, develop a clear reprocessing and single-use strategy that aligns clinical safety priorities with lifecycle economics; when pursuing reusable options, ensure validated cleaning protocols and staff training are in place. Fourth, embrace digital traceability and product identification systems to satisfy regulatory expectations, simplify recalls, and support inventory analytics; integrating traceability into procurement platforms will improve visibility across the lifecycle. Finally, build cross-functional governance teams that include clinical, procurement, regulatory, and quality stakeholders to accelerate supplier qualification and to ensure that product choices are evidence-driven and operationally feasible. Taken together, these measures will enhance supply continuity, enable cost control, and support safer patient care.

A transparent description of the multi-method research process, data validation techniques, and expert engagement approach used to produce actionable clinical and procurement insights

This research employed a structured, multi-method approach to ensure findings are robust, verifiable, and relevant to decision-makers. Primary evidence collection included interviews with clinical leaders, procurement specialists, and manufacturing quality experts to capture operational realities, device compatibility challenges, and supply-chain priorities. Secondary research drew on regulatory publications, standards documents, and peer-reviewed literature to ground analysis in current safety and performance expectations. Where applicable, product specifications and technical whitepapers were cross-referenced to validate claims about materials, sterilization compatibility, and device interfaces.

Analytical methods combined qualitative synthesis with scenario analysis to evaluate the implications of trade policy changes and regional supply constraints. Validation steps included triangulation across independent expert inputs and cross-checking of technical assertions against publicly available regulatory guidance. Throughout the process, attention was paid to excluding speculative financial metrics and instead emphasizing actionable operational, clinical, and strategic insights to inform procurement, product development, and policy decisions. Limitations are acknowledged where regional data granularity varies or where rapid policy changes necessitate ongoing monitoring to maintain relevance.

A definitive wrap-up highlighting the strategic priorities and coordinated actions required to secure clinical continuity, product safety, and procurement resilience in the evolving landscape

In conclusion, the blood tubing set landscape is at an inflection point where material innovation, regulatory rigor, and supply-chain agility will determine who succeeds in meeting evolving clinical needs. Providers and suppliers must reconcile competing imperatives: minimizing contamination and clinical risk, controlling recurring consumable costs, and maintaining supply continuity in the face of trade and logistics uncertainty. Organizations that integrate product design excellence with flexible sourcing and digital traceability will be best positioned to support expanding care models, including home-based therapies and high-throughput dialysis settings.

The path forward requires coordinated action across clinical, procurement, and manufacturing stakeholders to ensure product compatibility, validated reprocessing where applicable, and robust contingency planning. By aligning technical development with real-world clinical workflows and by investing in supplier diversification and traceability, stakeholders can improve patient safety while containing lifecycle costs. Continued monitoring of regulatory guidance, materials science advances, and trade policy developments will be essential to adapt strategies and sustain operational continuity as care delivery models evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Tubing Set Market, by Type

  • 8.1. Apheresis Sets
  • 8.2. Hemodialysis Sets
  • 8.3. Transfusion Sets

9. Blood Tubing Set Market, by Material

  • 9.1. Polyvinyl Chloride
  • 9.2. Thermoplastic Elastomer

10. Blood Tubing Set Market, by End-User

  • 10.1. Clinics
  • 10.2. Dialysis Centers
  • 10.3. Homecare
  • 10.4. Hospitals

11. Blood Tubing Set Market, by Usage

  • 11.1. Reusable
  • 11.2. Single-Use

12. Blood Tubing Set Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood Tubing Set Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood Tubing Set Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Blood Tubing Set Market

16. China Blood Tubing Set Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Angiplast Private Limited
  • 17.7. Asahi Kasei Corporation
  • 17.8. B. Braun Melsungen AG
  • 17.9. Baxter International Inc
  • 17.10. Becton Dickinson and Company
  • 17.11. Cardinal Health
  • 17.12. Danaher Corporation
  • 17.13. Fresenius Kabi AG
  • 17.14. GE HealthCare Technologies Inc
  • 17.15. Gerresheimer AG
  • 17.16. Haemonetics Corporation
  • 17.17. Hemant Surgical Industries Ltd
  • 17.18. ICU Medical Inc
  • 17.19. JMS Co., Ltd.
  • 17.20. Medtronic Plc
  • 17.21. Merit Medical Systems Inc
  • 17.22. Nipro Corporation
  • 17.23. NxStage Medical
  • 17.24. Shandong Weigao Group Medical Polymer
  • 17.25. Smith & Nephew PLC
  • 17.26. Smiths Medical
  • 17.27. Terumo Corporation
  • 17.28. Thermo Fisher Scientific
  • 17.29. Vyaire Medical

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD TUBING SET MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD TUBING SET MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD TUBING SET MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD TUBING SET MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD TUBING SET MARKET SIZE, BY USAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD TUBING SET MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD TUBING SET MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD TUBING SET MARKET SIZE, BY APHERESIS SETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD TUBING SET MARKET SIZE, BY APHERESIS SETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD TUBING SET MARKET SIZE, BY APHERESIS SETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HEMODIALYSIS SETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HEMODIALYSIS SETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HEMODIALYSIS SETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD TUBING SET MARKET SIZE, BY TRANSFUSION SETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD TUBING SET MARKET SIZE, BY TRANSFUSION SETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD TUBING SET MARKET SIZE, BY TRANSFUSION SETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD TUBING SET MARKET SIZE, BY POLYVINYL CHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD TUBING SET MARKET SIZE, BY POLYVINYL CHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD TUBING SET MARKET SIZE, BY POLYVINYL CHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD TUBING SET MARKET SIZE, BY THERMOPLASTIC ELASTOMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD TUBING SET MARKET SIZE, BY THERMOPLASTIC ELASTOMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD TUBING SET MARKET SIZE, BY THERMOPLASTIC ELASTOMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD TUBING SET MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD TUBING SET MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD TUBING SET MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD TUBING SET MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD TUBING SET MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD TUBING SET MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD TUBING SET MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD TUBING SET MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD TUBING SET MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD TUBING SET MARKET SIZE, BY SINGLE-USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD TUBING SET MARKET SIZE, BY SINGLE-USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD TUBING SET MARKET SIZE, BY SINGLE-USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD TUBING SET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS BLOOD TUBING SET MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA BLOOD TUBING SET MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. MIDDLE EAST BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AFRICA BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD TUBING SET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASEAN BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 86. GCC BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GCC BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 89. GCC BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 90. GCC BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPEAN UNION BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. BRICS BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 101. G7 BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. G7 BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 104. G7 BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. G7 BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 106. NATO BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NATO BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 109. NATO BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. NATO BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. UNITED STATES BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. CHINA BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)